7

Glioblastoma & Astrocytoma

149

mEHT + radiotherapy + chemotherapy (BSC, palliative range)

5y-OS = 83% (AST) in mEHT vs. 5y-OS = 25% by BSC. 5y-OS = 3.5% in mEHT vs. 5y-OS = 1.2% by BSC for GBM. Median OS = 14 m of mEHT for GBM and OS = 16.5 m for AST.

Fiorentini, Sarti, et al. 2019b [149]

8

Advanced hepatocell. carcinoma

21

Chemotherapy + mEHT

PR = 1, CR = 0, SD = 11. Combined therapy was effective, and no major complications were observed.

Gadaleta-Caldarola, et al. 2014 [150] ,

9

Refractory hepatocell. carcinoma

22

mEHT + thermo-active agents (TAA) or mEHT without TAA

CR = 1, PR = 0. Median OS = 20.5 weeks. 50% showed evidence of increasing QoL and minimal toxicity.

Ferrari, Ponti et al. 2007 [151]

10

Small-cell lung cancer (SCLC)

22

Chemotherapy + mEHT

mEHT enhanced destroying the cancer cells. Improved the OS of patients too.

Lee, Haam et al. 2013 [152]

11

Advanced cervical cancer

236

Random. Phase III (chemoradiation alone (CHR) and mEHT group (mEHT + CHR) [preliminary data]

Preliminary data for first 100 participants. A positive trend in survival and local disease control by mEHT. No significant differences in acute adverse events or quality of life between the groups.

Minnaar, Baeyens et al. 2016 [153]

12

Advanced cervical cancer

38

Chemotherapy + /− mEHT

The overall response (CR + PR + SD vs. PD) to was significantly greater with mEHT. No complications or extra adverse effect by mEHT.

Lee, Lee et al. 2017 [136]

13

Advanced cervical cancer

72

Radiotherapy + chemotherapy + mEHT

CR + PR = 73.5%; SD = 14.7%. The addition of mEHT increased the QoL and OS.

Pesti, et al. 2013 [139]

14

Advanced cervical carcinoma

20

mEHT + radiotherapy + chemotherapy

mEHT increases the peri-tumour temperature and blood flow in human cervical tumours, promoting the radiotherapy + chemotherapy.

Lee, Kim, et al. 2018 [154]

15

Advanced cervical carcinoma

108

mEHT + chemoradiotherapy

The metabolicly complete remnission (CMR) of disease outside the radiation field at 6 m post-treatment shows abscopal effect, significantly associated with the addition of mEHT.

Minnaar, Kotzen, et al. 2020b [155]

16

Advanced cervical carcinoma

206

Random. Phase III (chemoradiation alone (CHR) and mEHT group (mEHT + CHR) [preliminary data]

Compliance to mEHT treatment was high (97% completed ≥8 treatments) with no significant differences in CRT-related toxicity between treatment groups or between HIV-positive and -negative participants.

Minnaar, Kotzen, et al. 2020a [156]

17

Advanced cervical carinoma

202

mEHT + chemoradiotherapy

Six month local disease-free survival (LDFS) = 38.6% for mEHT and LDFS = 19.8% without mEHT (p = 0.003). Local disease control (LDC) = 45.5% with mEHT LDC = 24.1% without mEHT; (p = 0.003).

Minnaar, Kotzen, et al. 2019 [157]

18

Stage III-IV NSCLC

15

Ascorbic acid (AA) infusion + mEHT

AA safely synergies with mEHT and well tolerated, no major adverse effects

Ou, Zhu, et al. 2017 [158] ,

19

Advanced NSCLC

97

mEHT + radiotherapy + chemotherapy

Median OS = 9.4 m with mEHT OS = 5.6 m without mEHT; (p < 0.0001). Median PFS = 3 m for mEHT and PFS = 1.85 m without mEHT; p < 0.0001.

Ou, Zhu, et al. 2020 [159]

20

Advanced NSCLC

311 (61 + 197 + 53)

Radiotherapy + chemotherapy + mEHT

Two centres PFY (n = 61), HTT (n = 197) control (n = 53). 80% (PFY), 80% (HTT) had distant metastases, conventional therapies failed. Median OS = 16.4 m (PFY), 15.6 m (HTT), 14 m (control); 1st y survival 67.2% (PFY), 64% (HTT), 26.5% (control).

Dani, Varkonyi, et al. 2011 + Szasz, 2014b [160]